Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | CFTR | P13569 | 3/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25113886 | 1.00 | ADORA2A (0.34) | ADORA2AADORA2BADORA1CFTRGABRA5 | |
| SCHEMBL24986136 | 0.94 | CFTR (0.33) | ADORA2AADORA2BADORA1CFTRGABRA5 | |
| SCHEMBL24986135 | 0.94 | CFTR (0.33) | ADORA2AADORA2BADORA1CFTRGABRA5 | |
| SCHEMBL25114400 | 0.92 | CNR2 (0.31) | — | |
| SCHEMBL25114438 | 0.92 | CFTR (0.30) | CFTRGABRA5 | |
| SCHEMBL25114459 | 0.92 | CFTR (0.30) | CFTRGABRA5 | |
| SCHEMBL25114748 | 0.91 | CFTR (0.33) | CFTRGABRA5KLKB1 | |
| SCHEMBL25116223 | 0.91 | CFTR (0.33) | CFTRGABRA5KLKB1 | |
| SCHEMBL25114880 | 0.90 | ADORA2A (0.34) | ADORA2AADORA2BADORA1CFTRGABRA5 | |
| SCHEMBL25113983 | 0.90 | CFTR (0.32) | CFTRGABRA5KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230108803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230108803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | ADORA2A 1668/4885ADORA2B 1151/4885ADORA1 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.